81 related articles for article (PubMed ID: 7879247)
1. Efficacy of cytomegalovirus prophylaxis in renal retransplantation.
Singh TP; Gruber SA; Lempert N; Freed B; Conti DJ
Transplant Proc; 1995 Feb; 27(1):964-5. PubMed ID: 7879247
[No Abstract] [Full Text] [Related]
2. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease.
Conti DJ; Freed BM; Lempert N
Transplant Proc; 1993 Feb; 25(1 Pt 2):1421-2. PubMed ID: 8382867
[No Abstract] [Full Text] [Related]
3. Ganciclovir in cytomegalovirus prophylaxis in high-risk pediatric renal transplant recipients.
Prokurat S; Drabik E; Grenda R; Vogt E
Transplant Proc; 1993 Aug; 25(4):2577. PubMed ID: 8395104
[No Abstract] [Full Text] [Related]
4. Successful treatment of Epstein-Barr virus infection with ganciclovir and cytomegalovirus hyperimmune globulin following kidney transplantation.
Delone P; Corkill J; Jordan M; Krapiva P; Ghasemian R; Sasaki T; Light JA
Transplant Proc; 1995 Oct; 27(5 Suppl 1):58-9. PubMed ID: 7482823
[No Abstract] [Full Text] [Related]
5. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
[No Abstract] [Full Text] [Related]
6. Cytomegalovirus infection in pediatric kidney transplantation.
Fontana I; Verrina E; Timitilli A; Arcuri V; Basile G; Losurdo G; Rabagliati AM; Perfumo F; Giacchino R; Gusmano R
Transplant Proc; 1994 Feb; 26(1):18-9. PubMed ID: 8108929
[No Abstract] [Full Text] [Related]
7. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial.
Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL
Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072
[No Abstract] [Full Text] [Related]
8. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient.
Uber L; Cofer J; Baliga P; Rajagopalan PR
Transplant Proc; 1995 Oct; 27(5 Suppl 1):42-3. PubMed ID: 7482818
[No Abstract] [Full Text] [Related]
9. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
Ahsan N; Holman MJ; Yang HC
Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
[TBL] [Abstract][Full Text] [Related]
10. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
[TBL] [Abstract][Full Text] [Related]
11. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
12. [The significance of risk-adapted antiviral prophylaxis and modern viral diagnosis for organ survival after kidney transplantation].
Bach D; Will A; Grabensee B; Krempe C
Dtsch Med Wochenschr; 1997 Oct; 122(43):1334. PubMed ID: 9410702
[No Abstract] [Full Text] [Related]
13. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus hyperimmune globulin for CMV disease refractory to ganciclovir in renal transplantation.
Waid TH; McKeown JW
Transplant Proc; 1995 Oct; 27(5 Suppl 1):46. PubMed ID: 7482820
[No Abstract] [Full Text] [Related]
15. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
[TBL] [Abstract][Full Text] [Related]
16. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
[TBL] [Abstract][Full Text] [Related]
17. Management of cytomegalovirus infection in high-risk recipients after renal transplantation: prophylaxis by hyperimmunoglobulins or DHPG treatment?
Tenschert W; Gonnermann D; Meyer-Moldenhauer WH; Cremaschi L; Huland H
Transplant Proc; 1993 Dec; 25(6):3256-8. PubMed ID: 8266533
[No Abstract] [Full Text] [Related]
18. Efficacy of early treatment of cytomegalovirus infection by ganciclovir in renal transplant recipients.
Rondeau E; Farquet C; Ruedin P; Fries D; Sraer JD
Transplant Proc; 1990 Aug; 22(4):1813-4. PubMed ID: 2167536
[No Abstract] [Full Text] [Related]
19. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
van Son WJ; van den Berg AP; The TH; Tegzess AM
Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873
[No Abstract] [Full Text] [Related]
20. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection.
Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M
Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
